0

The full content of Annals is available to subscribers

Subscribe/Learn More  >
Articles |

Effect of Caffeine on the Recognition of and Responses to Hypoglycemia in Humans

David Kerr, MD; Robert S. Sherwin, MD; Frank Pavalkis, PA-C; Pierre B. Fayad, MD; Lori Sikorski, RN; Frances Rife, RN; William V. Tamborlane, MD; and Matthew J. During, MD
[+] Article and Author Information

From Yale University School of Medicine, New Haven, Connecticut. Requests for Reprints: David Kerr, MD, Royal Bournemouth Hospital, Castle Lane East, Bournemouth, Dorset, England BH7 7DW. Acknowledgments: The authors thank Aida Grossman and Andrea Belous for help with measurements of hormone levels, Val Pascale for his help with randomization and for supplying the drinks, and Dr. Lawrence M. Brass for his comments. Grant Support: By grants DK 20495, RR 00125, RR 06022, and NS 28227 from the National Institutes of Health and in part by gifts to the Yale Stroke Program.


Copyright 2004 by the American College of Physicians


Ann Intern Med. 1993;119(8):799-804. doi:10.7326/0003-4819-119-8-199310150-00005
Text Size: A A A

Objective: To determine whether two effects of acute caffeine ingestiondecrease in cerebral blood flow and increase in brain glucose usealter the recognition of and physiologic responses to hypoglycemia.

Design: On two occasions, a hyperinsulinemic glucose clamp technique (2 mU/kg body weight per minute) was used to maintain plasma glucose at 5 mmol/L for 90 minutes, followed by 60 minutes at 3.8 mmol/L, and then 2.8 mmol/L. After 30 minutes at 5 mmol/L, participants consumed, using a randomized, double-blind design, caffeine-free cola with or without caffeine (400 mg) added.

Setting: Yale Clinical Research Center.

Participants: Eight healthy, nonobese volunteers (5 men; age range, 20 to 33 years).

Measurements: Middle cerebral artery velocity (VMCA), counter-regulatory hormone levels, hypoglycemic symptoms, and cognitive function (P300 evoked potentials).

Results: Caffeine caused an immediate and sustained 23% decrease in VMCA from 64 to 49 cm/s (point estimate of difference, +15 cm/s [95% CI, 10 to 21 cm/s], P < 0.001). At a glucose level of 3.8 mmol/L, only the participants given caffeine had warning symptoms and felt hypoglycemic. Moreover, the level of epinephrine was 118% (CI of point difference, 76% to 158%; CI, P < 0.001) higher after caffeine consumption compared with placebo. Similarly, levels of norepinephrine (41% [CI, 26% to 60%], P < 0.002), cortisol (65% [CI, 26% to 78%], P < 0.008), and growth hormone (60% [CI, 16% to 143%], P < 0.05) were higher after caffeine consumption compared with placebo. At 2.8 mmol/L, epinephrine (40% [point estimate of the percentage difference], P < 0.05), norepinephrine (27%, P < 0.05), and cortisol (24%, P < 0.05) levels were higher, participants were more aware (P < 0.02) of hypoglycemia, and P300 latency was prolonged in the group that consumed caffeine (7.2%, P < 0.05).

Conclusions: Acute ingestion of caffeine is associated with sympathoadrenal activation and awareness of hypoglycemia at a glucose level not usually considered hypoglycemic. Our data suggest that individuals who ingest moderate amounts of caffeine may develop hypoglycemic symptoms if plasma glucose levels fall into the low-normal range, as might occur in the late postprandial period after ingestion of a large carbohydrate load.

Figures

Grahic Jump Location
Figure 1.
Mean ( SE) plasma glucose and caffeine levels during both studies.

After 30 minutes, a drink containing caffeine-free diet cola with or without caffeine (400 mg) was given. At baseline in the caffeine study and throughout the placebo study, plasma caffeine levels were below the limit of detection of the assay.

Grahic Jump Location
Grahic Jump Location
Figure 2.
Levels (mean SE) of epinephrine, norepinephrine, cortisol, and growth hormone.PPPPP

When plasma glucose was lowered to 3.8 mmol/L, epinephrine ( < 0.001), norepinephrine ( < 0.002), cortisol ( < 0.008), and growth hormone ( < 0.05) responses were greater after ingestion of caffeine compared with placebo. At a plasma glucose level of 2.8 mmol/L, epinephrine, norepinephrine, and cortisol (all < 0.05) levels were higher in the caffeine study. Glucagon levels were almost identical throughout each study (see text).

Grahic Jump Location
Grahic Jump Location
Figure 3.
Middle cerebral artery velocity and P300 latency.PP

The mean values ( SE) are shown at baseline (5 mmol/L), at the end of euglycemia, and when plasma glucose was lowered to 3.8 and to 2.8 mmol/L. Data shown are the average values for the final 20 minutes of each period. *** < 0.001 and * < 0.05 caffeine compared with placebo. Black bars depict caffeine; white bars, placebo.

Grahic Jump Location

Tables

References

Letters

NOTE:
Citing articles are presented as examples only. In non-demo SCM6 implementation, integration with CrossRef’s "Cited By" API will populate this tab (http://www.crossref.org/citedby.html).

Comments

Submit a Comment
Submit a Comment

Summary for Patients

Clinical Slide Sets

Terms of Use

The In the Clinic® slide sets are owned and copyrighted by the American College of Physicians (ACP). All text, graphics, trademarks, and other intellectual property incorporated into the slide sets remain the sole and exclusive property of the ACP. The slide sets may be used only by the person who downloads or purchases them and only for the purpose of presenting them during not-for-profit educational activities. Users may incorporate the entire slide set or selected individual slides into their own teaching presentations but may not alter the content of the slides in any way or remove the ACP copyright notice. Users may make print copies for use as hand-outs for the audience the user is personally addressing but may not otherwise reproduce or distribute the slides by any means or media, including but not limited to sending them as e-mail attachments, posting them on Internet or Intranet sites, publishing them in meeting proceedings, or making them available for sale or distribution in any unauthorized form, without the express written permission of the ACP. Unauthorized use of the In the Clinic slide sets will constitute copyright infringement.

Toolkit

Buy Now

to gain full access to the content and tools.

Want to Subscribe?

Learn more about subscription options

Advertisement
Related Articles
Related Point of Care
Topic Collections
Forgot your password?
Enter your username and email address. We'll send you a reminder to the email address on record.
(Required)
(Required)